Coronavirus Vaccine / Trial result of third phase of Covaxin released, effective up to 93% in serious case of corona

Indigenous vaccine manufacturer Bharat Biotech has completed the trial of the third and final phase of Covaxin Vaccine. Also, the company has officially released the third phase results. It was told that Covaxin has also been found to be effective on severe patients of corona and patients of delta variant.

Bharat Biotech said on the basis of the third phase results that Covaxin vaccine has been found to be 77.8% effective overall against corona.

Effective against Delta variants

At the same time, this vaccine has been found to be 65.2% effective against dangerous delta variants spreading panic across the world. Whereas Covaxin was reported to be 93.4% effective in preventing serious infections. It proved to be 63.6% effective on asymptomatic corona patients.

Efficacy of Covaxin 77.8%

The third phase trial of Covaxin showed that its overall efficiency was found to be 77.8%. Whereas its overall efficiency was found to be 93.4 percent on severe infection of corona virus.

It was reported that Covaxin is 67.8% effective for people above 60 years and 79.4% for people below 60 years. However, serious side effects were also observed in about 99 volunteers during the Phase III trial.

Know how effective is Covaxin in which case-

Asymptomatic cases: 63% effective

Delta Variant: 65% Effective

Mild, moderate and severe cases: 78% effective

Severe corona cases: 93% effective; Let us tell you that the company has conducted this trial on 130 confirmed cases of corona.